This landmark study is the first-ever side-by-side comparison of 171 antibodies against Ebola virus.
A one-two punch of powerful antibodies may be the best way to stop Ebola virus, reports an international team of scientists in the journal Cell. Their findings suggest new therapies should disable Ebola virus’s infection machinery and spark the patient’s immune system to call in reinforcements.
“This study presents results from an unprecedented international collaboration and demonstrates how 43 previously competing labs can together accelerate therapeutics and vaccine design,” says Erica Ollmann Saphire, PhD, professor at Scripps Research and director of the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC).
From 2013–2016, West Africa faced the deadliest Ebola outbreak the world has ever seen. By the time the outbreak was declared over, 11,325 people had died. The VIC is an international group of the world’s leading virologists, immunologists, systems biologists and structural biologists working to stop an outbreak on that scale from ever striking again.
The VIC researchers aim to understand which Ebola-fighting antibodies are best—and why. The hope is that the most effective antibodies can be combined in a therapeutic “cocktail.” Unlike an Ebola vaccine, these cocktails could be given to those already infected, which is important for stopping a disease that tends to emerge unexpectedly in remote locations.
Ollmann Saphire and her colleagues in the VIC have published more than 40 studies in just the last five years. This landmark study is the first-ever side-by-side comparison of 171 antibodies against Ebola virus and other related viruses, known as filoviruses. All antibodies in the panel were donated by different labs around the world, and many had not been previously characterized in such extensive detail.
“Through the VIC, we could test a larger pool of antibodies in parallel, which increased the potential to detect statistically significant relationships between antibody features and protection,” says Saphire. “We used this global pool of antibodies to evaluate, and streamline, the research pipeline itself.”
In addition to identifying links between antibody target locations and activity, VIC researchers tested this huge pool of antibodies to reveal which antibodies “neutralized” the virus, why neutralization assays so often disagree, and whether or not neutralization in test tubes adequately predicted how well these antibodies would protect live animals from Ebola virus infection. Unexpectedly, neutralization alone was not always associated with the protective ability of an antibody.
Notably, the scientists found nine antibodies that protected mice from infection without neutralizing the virus in test tubes. These antibodies likely fight infection by interacting with an infected person’s immune system, helping orchestrate a better immune response to the virus.
This “immune effector” activity is featured in the team’s companion study published simultaneously in Cell Host & Microbe. “The ability to evoke an immune response will likely represent a new avenue of study for therapeutic antibodies for Ebola virus infection,” says Sharon Schendel, project manager for the VIC and science writer in the Saphire lab.
From the large body of results, VIC member and Scripps Research faculty member Kristian Andersen, PhD, and his graduate student Karthik Gangavarapu developed a network describing how each antibody feature correlates to protection, which can serve as a guide to predict whether newly identified antibodies will have therapeutic value. Saphire says the next steps for the VIC are to further test promising antibody cocktails in non-human primates. The team will also pursue engineering of antibodies that carry signature features to better drive immune system response.
The Latest on: Ebola
via Google News
The Latest on: Ebola
- UCF Study Shows Hope for Fighting Disease Known as Ebola Frogs on February 19, 2019 at 5:10 am
Despite widespread infection, some frog populations are surviving a deadly disease that is the equivalent of mankind’s Ebola virus. The reason —genetic diversity. That’s the finding of a new study pub... […]
- Ebola Virus Vaccine Market: Comprehensive study explores Huge Growth in Future | Leading Key Players- Crucell, Fab Entech, Inovio Pharmaceuticals on February 19, 2019 at 2:44 am
Latest research study from HTF MI with title Global Ebola Virus Vaccine by Manufacturers, Regions, Type and Application, Forecast to 2023. The Research report presents a complete assessment of the mar... […]
- Ebola Survivor Tells How She Denied Disease Existed on February 19, 2019 at 1:58 am
When Jémima Masika, 26, lost her parents to the deadly Ebola virus in August last year, she thought the disease was a myth. Then her worst nightmare came true: she contracted the disease while ... […]
- DR Congo: Tackling Ebola in a War Zone on February 18, 2019 at 5:56 pm
Since August, the Democratic Republic of the Congo (DR Congo) has been facing the worst Ebola outbreak in its history. Violence and armed conflict in the region have made outbreak response a ... […]
- The Next Ebola Outbreak Is Hard to Predict, but "Outbreak Forecasting" Can Help on February 18, 2019 at 4:58 pm
A 2-year-old boy in rural Guinea died of Ebola in December 2014. Over the next two years, almost 30,000 people in West Africa would be infected with the Ebola virus. Why, unlike the previous 17 Ebola ... […]
- Surviving Ebola: “I was so afraid to die and be put in a body bag” on February 18, 2019 at 3:00 pm
BENI, Democratic Republic of the Congo – When Jémima Masika, 26, lost her parents to Ebola in August, she thought deadly virus was a myth – then she fell sick herself. “I did not believe in the existe... […]
- Breaking Down Community Resistance in Ebola-Affected Congo on February 17, 2019 at 7:34 am
A unique project is making strides in breaking down community resistance toward international efforts to contain the spread of the deadly Ebola virus in the eastern Democratic Republic of Congo. The I... […]
- New Ebola treatments are being tested in Congo outbreak area on February 17, 2019 at 5:00 am
Amid the second-largest Ebola outbreak ever, the hunt for a lifesaving treatment is on. A clinical trial of patients taking place in Congo is gathering evidence on experimental therapies, to provide a ... […]
- Hope for fighting disease known as Ebola of frogs on February 15, 2019 at 2:30 pm
Despite widespread infection, some frog populations are surviving a deadly disease that is the equivalent of humankind's Ebola virus. The reason -- genetic diversity. Despite widespread infection, som... […]
via Bing News